Skip to content

Discontinued — last reported Q1 '26

EBIT at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.65M+81.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$110.03M-3.2%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$107.22M+10.1%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$36.92M+13.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's EBIT?
Disc Medicine (IRON) reported EBIT of -$69.52M in Q1 2026.
How has Disc Medicine's EBIT changed year-over-year?
Disc Medicine's EBIT decreased by 74.0% year-over-year, from -$39.95M to -$69.52M.
What is the long-term trend for Disc Medicine's EBIT?
Over 3 years (2022 to 2025), Disc Medicine's EBIT has grown at a 70.7% compound annual growth rate (CAGR), from -$47.48M to -$236.02M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.